PACIRA BIOSCIENCES INC. - COMMON STOCK

Pacira to Report 2024 Financial Results on Thursday February 27, 2025

20 Feb 2025 08:00:00 By Nasdaq GlobeNewswire

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06 Feb 2025 08:00:00 By Nasdaq GlobeNewswire

Pacira Announces Updates to Board of Directors

30 Jan 2025 08:00:00 By Nasdaq GlobeNewswire

Pacira BioSciences Strengthens Executive Leadership Team with Two Key Appointments

21 Jan 2025 08:00:01 By Nasdaq GlobeNewswire

Pacira Announces New Five-Year Objectives to Accelerate Transition into an Innovative Biopharmaceutical Organization

10 Jan 2025 08:00:00 By Nasdaq GlobeNewswire

Pacira BioSciences Receives FDA 510k Clearance for New iovera° SmartTip to Manage Chronic Low Back Pain via Long-lasting Medial Branch Nerve Block

07 Jan 2025 08:00:00 By Nasdaq GlobeNewswire

Pacira BioSciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference

02 Jan 2025 16:01:00 By Nasdaq GlobeNewswire

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

06 Dec 2024 08:00:00 By Nasdaq GlobeNewswire

Pacira Awarded New U.S. Patent Covering EXPAREL Composition

03 Dec 2024 07:30:00 By Nasdaq GlobeNewswire

Pacira Announces 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee

14 Nov 2024 10:05:00 By Nasdaq GlobeNewswire

Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences

12 Nov 2024 08:00:01 By Nasdaq GlobeNewswire

Pacira BioSciences Reports Third Quarter 2024 Financial Results

06 Nov 2024 16:00:00 By Nasdaq GlobeNewswire

Centers for Medicare and Medicaid Services (CMS) Establishes Additional Payment for iovera in Outpatient Settings

04 Nov 2024 08:00:00 By Nasdaq GlobeNewswire

Pacira to Report Third Quarter 2024 Financial Results on Wednesday November 6, 2024

30 Oct 2024 08:00:00 By Nasdaq GlobeNewswire

Pacira BioSciences Appoints Shawn Cross as Chief Financial Officer

21 Oct 2024 08:00:00 By Nasdaq GlobeNewswire

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

07 Oct 2024 08:00:00 By Nasdaq GlobeNewswire

Pacira BioSciences Announces New Product-Specific J-Code for EXPAREL Effective January 1, 2025

03 Oct 2024 08:00:43 By Nasdaq GlobeNewswire

Pacira Announces the Presentation of 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee

26 Sep 2024 08:00:00 By Nasdaq GlobeNewswire

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

09 Sep 2024 16:00:00 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: PACIRA BIOSCIENCES INC. - COMMON STOCK

13 Aug 2024 09:46:30 By NetDania Notify